Skip to main content

This website is intended for use by US residents only.

Prescribing Information location icon US patients website
CRYSVITA® (burosumab-twza) injection 10, 20, 30 mg/mL

Choose indication

Enrollment form Request a rep
Practice resources

CRYSVITA resources for HCPs treating XLH

Explore these CRYSVITA resources designed to help HCPs navigate treatment for pediatric and adult patients with X-linked hypophosphatemia (XLH).

Kyowa Kirin Cares CRYSVITA enrollment form

Kyowa Kirin Cares CRYSVITA enrollment form

A form to enroll patients who have been prescribed CRYSVITA into the Kyowa Kirin Cares program.

DOWNLOAD download icon
CRYSVITA start guide for healthcare professionals

CRYSVITA start guide for HCPs

A guide that walks through the steps of getting patients started on CRYSVITA—from patient enrollment and coverage authorization to product acquisition and delivery.

How to use CRYSVITA guide

How to use CRYSVITA guide

A guide with essential tips for HCPs on preparation, administration, product storage, and handling of CRYSVITA.

Clinical practice guidelines for children with XLH

Clinical Practice Guidelines for children with XLH

An overview of International Working Group treatment recommendations for managing XLH in children.

DOWNLOAD download icon
Clinical practice guidelines for adults with XLH

Clinical Practice Guidelines for adults with XLH

An overview of International Working Group treatment recommendations for managing XLH in adults.

DOWNLOAD download icon
Join the Specialist Finder form

Join the Specialist Finder

Are you an XLH specialist that would like to be added to the Finder? Opt in today.

Opt in to the Finder arrow icon

Case studies in XLH for HCPs

Adult XLH case study

ADULT CASE STUDY

37-year-old female with XLH on CRYSVITA

A patient case study adapted from a real-life example that provides medical history, diagnosis, and treatment information for an adult patient with inherited XLH.

Pediatric XLH case study

PEDIATRIC CASE STUDY

4-year-old male with spontaneous XLH on CRYSVITA

A patient case study adapted from a real-life example that provides medical history, diagnosis, and treatment information for a pediatric patient with spontaneous XLH.

Patient resources

CRYSVITA resources for patients with XLH and caregivers

Explore helpful CRYSVITA resources with your patients, ranging from patient events to family support guides.

Brochure for adult patients with XLH

Brochure for adults with XLH

A brochure for adults with XLH who want to learn more about how CRYSVITA can help treat their condition.

DOWNLOAD download icon
Brochure for caregivers of children with XLH

Brochure for caregivers of children with XLH

A brochure for caregivers of children with XLH who want to learn more about how CRYSVITA treatment may be able to help their child.

DOWNLOAD download icon
Specialist finder tool

Specialist Finder

A tool to help patients and caregivers find an HCP near them with experience managing XLH.

Specialist Finder arrow icon

Educational events for patients with XLH and caregivers

Encourage your patients to attend an event to learn more about CRYSVITA from XLH specialists and to connect with others in the XLH community.

SEE ALL EVENTS arrow icon

Connecting with others in the XLH community

The groups listed below provide support and education for people living with XLH.

Information listed for educational purposes only. This is a curated list and is not meant to be an exhaustive list of all organizations, services, or online resources. These resources are created by and hosted on third-party websites that are not reviewed, controlled, or endorsed by Kyowa Kirin, Inc.

The XLH Network

The XLH Network

The XLH Network, a 501(c)(3) nonprofit organization, seeks to connect people around the world who are affected by or interested in learning more about XLH. The XLH Network connects affected individuals, families, and medical professionals.

The XLH Network arrow icon
National Organization for Rare Disorders

National Organization for Rare Disorders (NORD)

NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them.

National Organization for Rare Disorders (NORD)

arrow icon
Global Genes

Global Genes

Global Genes is a rare disease patient advocacy organization that works to build awareness, educate the global community, and provide connections and resources.

Global Genesarrow icon
Got Transition

Got Transition

Got Transition is the national resource center for healthcare transition. Its aim is to improve the transition from pediatric to adult health care through the use of evidence-driven strategies for HCPs, youth, young adults, and their caregivers.

Stay connected

Set up time with a representative to talk more about CRYSVITA or sign up for more information on CRYSVITA for the treatment of XLH.

Request a Rep SIGN UP
A doctor smiling at someone

Actor portrayal

Indication

CRYSVITA® (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.

read more
Indication

CRYSVITA® (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.

Important Safety Information

CONTRAINDICATIONS

CRYSVITA is contraindicated:

  • In concomitant use with oral phosphate and/or active vitamin D analogs (e.g., calcitriol, paricalcitol, doxercalciferol, calcifediol) due to the risk of hyperphosphatemia.
  • When serum phosphorus is within or above the normal range for age.
  • In patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism.

WARNINGS AND PRECAUTIONS

Hypersensitivity

  • Hypersensitivity reactions (e.g., rash, urticaria) have been reported in patients with CRYSVITA. Discontinue CRYSVITA if serious hypersensitivity reactions occur and initiate appropriate medical treatment.

Hyperphosphatemia and Risk of Nephrocalcinosis

  • Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis. For patients already taking CRYSVITA, dose interruption and/or dose reduction may be required based on a patient’s serum phosphorus levels.

Hypercalcemia

  • Increases in serum calcium have been reported in patients treated with CRYSVITA. Patients with risk factors such as pre-existing hyperparathyroidism, prolonged immobilization, dehydration, hypervitaminosis D, or renal impairment, are at higher risk of hypercalcemia. Monitor these patients for serum calcium and parathyroid hormone levels before and during CRYSVITA treatment for moderate to severe hypercalcemia. In patients with moderate to severe hypercalcemia, CRYSVITA should not be administered until hypercalcemia is adequately managed.

Injection Site Reactions

  • Administration of CRYSVITA may result in local injection site reactions. Discontinue CRYSVITA if severe injection site reactions occur and administer appropriate medical treatment.

ADVERSE REACTIONS

Pediatric Patients

  • Adverse reactions reported in 10% or more of CRYSVITA-treated pediatric XLH patients across three studies are: pyrexia (55%, 44%, and 62%), injection site reaction (52%, 67%, and 23%), cough (52%), vomiting (41%, 48%, and 46%), pain in extremity (38%, 46%, and 23%), headache (34% and 73%), tooth abscess (34%, 15%, and 23%), dental caries (31%), diarrhea (24%), vitamin D decreased (24%, 37%, and 15%), toothache (23% and 15%), constipation (17%), myalgia (17%), rash (14% and 27%), dizziness (15%), and nausea (10%).

Adult Patients

  • Adverse reactions reported in more than 5% of CRYSVITA-treated adult XLH patients and in at least 2 patients more than placebo in one study are: back pain (15%), headache (13%), tooth infection (13%), restless legs syndrome (12%), vitamin D decreased (12%), dizziness (10%), constipation (9%), muscle spasms (7%), and blood phosphorus increased (6%).
  • Spinal stenosis is prevalent in adults with XLH, and spinal cord compression has been reported. It is unknown if CRYSVITA therapy exacerbates spinal stenosis or spinal cord compression.

USE IN SPECIFIC POPULATIONS

  • There are no available data on CRYSVITA use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Serum phosphorus levels should be monitored throughout pregnancy. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • There is no information regarding the presence of CRYSVITA in human milk or the effects of CRYSVITA on milk production or the breastfed infant. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CRYSVITA and any potential adverse effects on the breastfed infant from CRYSVITA or from the underlying maternal condition.

PATIENT COUNSELING INFORMATION

  • Advise patients not to use any oral phosphate and/or active vitamin D analog products.
  • Instruct patients to contact their physician if hypersensitivity reactions, injection site reactions, and restless legs syndrome induction or worsening of symptoms occur.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information for CRYSVITA.

Indication

CRYSVITA® (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.

Important Safety Information

CONTRAINDICATIONS

CRYSVITA is contraindicated:

  • In concomitant use with oral phosphate and/or active vitamin D analogs (e.g., calcitriol, paricalcitol, doxercalciferol, calcifediol) due to the risk of hyperphosphatemia.
  • When serum phosphorus is within or above the normal range for age.
  • In patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism.

WARNINGS AND PRECAUTIONS

Hypersensitivity

  • Hypersensitivity reactions (e.g., rash, urticaria) have been reported in patients with CRYSVITA. Discontinue CRYSVITA if serious hypersensitivity reactions occur and initiate appropriate medical treatment.

Hyperphosphatemia and Risk of Nephrocalcinosis

  • Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis. For patients already taking CRYSVITA, dose interruption and/or dose reduction may be required based on a patient’s serum phosphorus levels.

Hypercalcemia

  • Increases in serum calcium have been reported in patients treated with CRYSVITA. Patients with risk factors such as pre-existing hyperparathyroidism, prolonged immobilization, dehydration, hypervitaminosis D, or renal impairment, are at higher risk of hypercalcemia. Monitor these patients for serum calcium and parathyroid hormone levels before and during CRYSVITA treatment for moderate to severe hypercalcemia. In patients with moderate to severe hypercalcemia, CRYSVITA should not be administered until hypercalcemia is adequately managed.

Injection Site Reactions

  • Administration of CRYSVITA may result in local injection site reactions. Discontinue CRYSVITA if severe injection site reactions occur and administer appropriate medical treatment.

ADVERSE REACTIONS

Pediatric Patients

  • Adverse reactions reported in 10% or more of CRYSVITA-treated pediatric XLH patients across three studies are: pyrexia (55%, 44%, and 62%), injection site reaction (52%, 67%, and 23%), cough (52%), vomiting (41%, 48%, and 46%), pain in extremity (38%, 46%, and 23%), headache (34% and 73%), tooth abscess (34%, 15%, and 23%), dental caries (31%), diarrhea (24%), vitamin D decreased (24%, 37%, and 15%), toothache (23% and 15%), constipation (17%), myalgia (17%), rash (14% and 27%), dizziness (15%), and nausea (10%).

Adult Patients

  • Adverse reactions reported in more than 5% of CRYSVITA-treated adult XLH patients and in at least 2 patients more than placebo in one study are: back pain (15%), headache (13%), tooth infection (13%), restless legs syndrome (12%), vitamin D decreased (12%), dizziness (10%), constipation (9%), muscle spasms (7%), and blood phosphorus increased (6%).
  • Spinal stenosis is prevalent in adults with XLH, and spinal cord compression has been reported. It is unknown if CRYSVITA therapy exacerbates spinal stenosis or spinal cord compression.

USE IN SPECIFIC POPULATIONS

  • There are no available data on CRYSVITA use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Serum phosphorus levels should be monitored throughout pregnancy. Report pregnancies to the Kyowa Kirin, Inc. Adverse Event reporting line at 1-844-768-3544.
  • There is no information regarding the presence of CRYSVITA in human milk or the effects of CRYSVITA on milk production or the breastfed infant. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CRYSVITA and any potential adverse effects on the breastfed infant from CRYSVITA or from the underlying maternal condition.

PATIENT COUNSELING INFORMATION

  • Advise patients not to use any oral phosphate and/or active vitamin D analog products.
  • Instruct patients to contact their physician if hypersensitivity reactions, injection site reactions, and restless legs syndrome induction or worsening of symptoms occur.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Kyowa Kirin, Inc. at 1-844-768-3544.

For important risk and use information, please see the full Prescribing Information for CRYSVITA.

Back to top

COMM-US-CRY-0779 June 2026